![]() Research showed that success was inversely proportional to time between initial pain diagnosis and implantation, and the Neuromodulation Appropriateness Consensus Committee (NACC) recommended that SCS be considered and trialed within the first 2 years of chronic pain. ![]() In the treatment algorithm, SCS performed early in the course of patients’ chronic pain processes is associated with better outcomes than SCS performed late in the disease. ![]() The efficacy, safety, and cost-effectiveness of traditional SCS for chronic pain conditions are well-established with level 1 and level 2 evidence. Currently, the annual worldwide SCS system implantation rate is between 35,000 and 50,000 units. Electrical stimulation of the spinal cord is approved by the Food and Drug Administration for chronic painful disorders of the trunk and extremities such as failed back surgery syndrome and complex regional pain syndrome types I and II. SCS targets the dorsal columns of the spinal cord for relief of neuropathic pain. Spinal cord stimulation (SCS) has become an important tool in the management of otherwise intractable pain and can be a life-changing therapy for many patients. In the United States alone, an estimated 7.9 million adults experience chronic back pain. Chronic back pain affects a large portion of the global population, costing billions in direct and indirect medical costs and disrupting the lives of millions of people.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |